Company news
Entrada Therapeutics, Inc. (NASDAQ:TRDA) news
Entrada Therapeutics, Inc. news releases on 6ix. Latest, Sep 10, 2026: Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
Press releases & updates
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
September 10, 2026
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
August 5, 2026
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
June 2, 2026
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 7, 2026
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 6, 2026
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
February 25, 2026
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
February 17, 2026
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 4, 2026
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
January 8, 2026
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 4, 2025
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
November 6, 2025
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
September 5, 2025
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
August 6, 2025
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
June 3, 2025
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
May 28, 2025
Entrada Therapeutics Reports First Quarter 2025 Financial Results
May 8, 2025
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
March 24, 2025
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
February 24, 2025
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
February 2, 2025
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
November 4, 2024
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
October 8, 2024
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
September 23, 2024
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
September 5, 2024
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
August 12, 2024
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
June 23, 2024
Entrada Therapeutics Announces $100 Million Registered Direct Offering
June 23, 2024
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 2, 2024
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 15, 2024
Entrada Therapeutics Reports First Quarter 2024 Financial Results
May 6, 2024
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024
Entrada Therapeutics Promotes Nathan J. Dowden to President
January 2, 2024
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
November 21, 2023
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
November 6, 2023
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
September 20, 2023
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
September 6, 2023
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
August 9, 2023
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
August 7, 2023
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
July 31, 2023
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 5, 2023
Entrada Therapeutics Reports First Quarter 2023 Financial Results
May 9, 2023
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
April 3, 2023
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
March 28, 2023
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 5, 2023
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
February 26, 2023
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
February 8, 2023
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
January 8, 2023
Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy
December 18, 2022